Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGMO | Sangamo Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-1.18 Insider Own0.20% Shs Outstand174.32M Perf Week-22.80%
Market Cap136.77M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float152.32M Perf Month-14.96%
Income-198.50M PEG- EPS next Q-0.32 Inst Own61.50% Short Float / Ratio6.86% / 7.02 Perf Quarter-35.17%
Sales218.50M P/S0.63 EPS this Y-1.00% Inst Trans8.09% Short Interest10.46M Perf Half Y-54.62%
Book/sh1.34 P/B0.58 EPS next Y12.60% ROA-41.30% Target Price6.01 Perf Year-84.78%
Cash/sh0.81 P/C0.96 EPS next 5Y- ROE-67.70% 52W Range0.77 - 5.27 Perf YTD-75.43%
Dividend- P/FCF- EPS past 5Y-12.30% ROI-68.40% 52W High-85.36% Beta1.13
Dividend %- Quick Ratio3.00 Sales past 5Y24.90% Gross Margin- 52W Low0.19% ATR0.08
Employees478 Current Ratio3.00 Sales Q/Q-76.90% Oper. Margin-98.80% RSI (14)33.97 Volatility9.08% 9.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-125.40% Profit Margin-90.90% Rel Volume0.44 Prev Close0.81
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume1.49M Price0.77
Recom2.20 SMA20-16.38% SMA50-28.60% SMA200-60.12% Volume656,908 Change-4.82%
Date Action Analyst Rating Change Price Target Change
Apr-28-23Downgrade BofA Securities Neutral → Underperform $5 → $1.50
Feb-27-23Upgrade Wedbush Neutral → Outperform $16
Jan-06-23Downgrade BofA Securities Buy → Neutral $8 → $5
Jun-13-22Resumed Wedbush Neutral $5
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Dec-16-20Resumed H.C. Wainwright Buy $25
Sep-08-20Initiated BofA Securities Buy $20
Jul-07-20Initiated SunTrust Buy $22
Sep-20-23 04:15PM
Aug-25-23 01:38PM
Aug-08-23 05:30PM
04:15PM Loading…
Aug-01-23 04:15PM
Jul-20-23 08:05AM
Jul-19-23 07:08AM
Jul-17-23 08:05AM
Jun-29-23 08:05AM
Jun-28-23 09:20AM
Jun-14-23 08:16AM
May-22-23 08:05AM
May-18-23 07:04AM
May-16-23 08:00AM
04:30PM Loading…
May-02-23 04:30PM
Apr-26-23 05:28PM
Apr-25-23 02:39PM
Apr-21-23 04:58AM
Apr-19-23 04:15PM
Apr-17-23 07:38AM
Apr-16-23 06:30AM
Mar-23-23 06:09AM
Mar-21-23 09:35AM
Mar-20-23 12:25PM
Mar-10-23 09:35AM
Feb-25-23 08:26AM
Feb-23-23 05:36PM
05:25PM Loading…
Feb-22-23 05:25PM
Feb-21-23 09:01AM
Feb-16-23 10:01AM
Feb-13-23 09:55AM
Feb-10-23 11:01AM
Jan-30-23 07:10PM
Dec-06-22 06:02AM
Nov-09-22 05:31AM
Nov-03-22 05:55PM
Oct-27-22 04:15PM
Oct-14-22 09:49AM
Oct-12-22 08:55AM
Sep-23-22 12:02PM
Sep-18-22 09:11AM
Aug-30-22 08:50AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-04-22 05:45PM
Jul-28-22 04:15PM
Jul-21-22 08:05AM
Jul-18-22 09:21AM
Jun-07-22 08:55AM
Jun-01-22 04:30PM
May-08-22 08:09AM
May-05-22 05:45PM
May-04-22 06:35PM
May-02-22 04:30PM
Apr-28-22 04:15PM
Apr-21-22 04:30PM
Apr-11-22 08:59AM
Mar-30-22 06:40AM
Mar-29-22 08:05AM
Feb-28-22 05:00PM
Feb-24-22 06:20PM
Feb-17-22 04:30PM
Feb-08-22 11:32AM
Feb-07-22 06:00PM
Jan-21-22 05:38PM
Jan-13-22 01:38PM
Jan-06-22 08:00AM
Jan-04-22 05:00PM
Dec-20-21 05:29PM
Dec-13-21 10:54AM
Dec-12-21 04:30PM
Dec-10-21 09:34AM
Nov-22-21 07:00AM
Nov-18-21 05:54PM
Nov-09-21 08:30AM
Nov-08-21 10:13AM
Nov-04-21 10:01PM
Oct-28-21 04:30PM
Oct-27-21 03:03PM
Oct-11-21 03:29PM
Aug-31-21 08:30AM
Aug-10-21 05:21AM
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.